psalexa
logo

Ovarian Cancer Therapeutics Pipeline Analysis

Ovarian Cancer Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11261
Available Format:

Ovarian Cancer is a tumour that arises from the ovaries or areas of peritoneum or fallopian tube. Ovarian cancer can be symptomized by pain or swelling in the abdomen, gastrointestinal problems such as constipation and gas, pain in the pelvis, and vaginal bleeding. There are several risk factors for occurrence of ovarian cancer such as breast cancer, uterine cancer or colon cancer, endometriosis, have never given birth, having genetic mutation in BRCA1 or BRCA2 gene and patients associated with lynch syndrome. Morphotek, Inc. is in the process of developing farletuzumab as a folate receptor 1 antagonist for the treatment of ovarian cancer. AstraZeneca plc is in the process of developing OLAPARIB as a poly(ADP-ribose) polymerase inhibitor for the treatment of ovarian cancer. Some of the companies having the pipeline of ovarian cancer include Myriad Genetic Laboratories, Inc., Tesaro, Inc., Adaptimmune Therapeutics plc, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry